Bioxyne Limited · ASX:BXN
Bioxyne — H1 2025 Earnings Presentation
23 slides from Bioxyne's earnings presentation, Feb 28, 2025
Slide 1: H1 FY25 Results
H1 FY25 Results Becoming Australia’s leading manufacturer & wholesaler of novel medicines ASX:BXN Investor Presentation | February 2025 Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this p
Slide 3: Investment Highlights
Investment Highlights Record revenue growth of Extensive Good First company licensed by Diversified core of healthcare 171% to $12.6m for H1 FY25 on Manufacturing Practice TGA in Australia to & wellness revenue streams, PCP. Achieving positive (GMP) licence issued by TGA manufacture Psilocybin & fro
Slide 4: H1 FY25 Results
H1 FY25 Results Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 4
Slide 5: H1 FY25 Performance
H1 FY25 Performance Strong performance from provision of multiple cannabis focussed SKU’s with material pipeline of contracted revenue BXN REVENUS FROM OPERATIONS ($000’s) $25,000 $25,000 100% ~$12.6m 171% $20,000 80% Total Revenue for H1 FY25 Increase in revenue on the prior corresponding period (P
Slide 6: H1 FY25 Performance (cont.)
H1 FY25 Performance (cont.) Strong outlook for remainder of FY25 and beyond, following execution of significant contracts, further diversifying the customer base and derisking the revenue profile BXN HALF-YEAR PERFORMANCE (000’s) $12,563 • BXN has delivered positive cash flow from operations 12,000
Slide 7: H1 FY25 Performance (cont.)
H1 FY25 Performance (cont.) BXN continues to benefit from operational leverage following cost reduction initiatives & material increase in topline revenue Profit & Loss ($000's) H1 FY25 H1 FY24 Comment H1 FY25 Results Waterfall (000's) Revenue from continuing operations $12,563 Sale of goods 12,563
Slide 8: Outlook
Outlook Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 8
Slide 9: Near-Term Growth Strategy
Near-Term Growth Strategy As sales volumes for H2 become clearer the Board will continue to assess an increase to its FY25 stated guidance of $25m in revenue Exceed revenue Execute new high-value manufacture Increase investment in sales and Continue to bolster and optimise guidance of $25m as forwar
Slide 10: Expanding Production Capability
Expanding Production Capability Recent investment into additional equipment & facilities will provide substantial increased production capability at Australian sites SKU THC Flower THC & CBD Pastilles Vapes Oral Liquids / Oils Current Output $34,000 – $40,000 $99,000 $27,000 $35,000 (revenue per day
Slide 11: Company Overview
Company Overview Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 11
Slide 12: Commercial Milestones to Date
Commercial Milestones to Date Acquisition of Breathe Completed PICs GMP facility Strategic alliance with CY BLS manufactures BXN announces cash BXN releases H1 FY25 Production & supply of BXN Life Sciences (BLS) in QLD, with modular Biopharma AG to develop new Australia’s first GMP flow positive qua
Slide 13: Breathe Life Sciences’ Supply Chain Model
Breathe Life Sciences’ Supply Chain Model Product List1,2 Wholesalers Herb, Dried (Flower) Prescriptions - 3,347,909 Oral Liquid Prescriptions - 3,025,118 Clinics Capsules Prescriptions – 339,791 Inhalation (Vapes) Prescriptions – 133,116 Raw Materials Manufacture Pharmacy Patient1 Purchase raw Prod
Slide 14: Significant Market Opportunity
Significant Market Opportunity Bioxyne has established a global supply, manufacture and distribution network, now rapidly scaling revenues to service both the B2B & B2C market across all products. $39.1B Europe $12.5B Asia $37.9B North America Estimated Market Size Suppliers $9.1B Latin America & Ex
Slide 15: Key Market Opportunity
Key Market Opportunity Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 15
Slide 16: Growing Domestic Demand for Medicinal Cannabis
Growing Domestic Demand for Medicinal Cannabis Australian Medicinal Cannabis Prescriptions1 Australian Cannabis Market2 $1,000m 2024 137,180 2023 127,790 $800m 2022 114,930 $600m 2021 121,940 2020 57,710 $400m 2019 25,160 $200m 2018 2,560 2017 231 - 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Slide 17: Cannabis & CBD Market in Europe
Cannabis & CBD Market in Europe Europe’s medical cannabis market continues to see strong growth, presenting BXN with a significant opportunity to expand manufacturing, supply and distribution capabilities Legislation & Regulation of Cannabis in Europe1 BLS Europe Growth Opportunity3,4 Germany UK Cze
Slide 18: Appendix
Appendix Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 18
Slide 19: Balance Sheet
Balance Sheet Balance Sheet ($000's) H1 FY25 H1 FY24 Comment Assets Current Assets Cash and cash equivalents 2,679 1,028 Trade receivables 2,260 978 Current tax receivables 419 545 Other current assets 2,636 892 Prepayments to secure raw material pipeline Inventories 3,674 2,142 Total Current Assets
Slide 20: Cash Flow
Cash Flow Cash Flow ($000's) H1 FY25 H1 FY24 Comment Cash flows from operating activities Receipts from customers (incl. of GST) 13,211 4,672 In line with increase in sales revenue and purchase order deposits Payments to suppliers and employees (incl. of GST) (10,199) (6,910) Interest paid (55) - In
Slide 21: Experienced Leadership Team
Experienced Leadership Team Mr. Anthony Ho Samuel Watson Jason Hine Guy Robertson B. Com (UNSW), CA, FAICD, FCIS, FGIA BSc Finance and Economics BA Economics and Commerce B. Com (Hons.) CA Non-executive Chairman Managing Director Executive Director CFO & Company Secretary • Tony is an experienced co
Slide 22: Corporate Overview
Corporate Overview $0.06 90m $0.04 60m $0.02 30m - - Feb-24 May-24 Aug-24 Nov-24 Feb-25 Volume Share Price CORPORATE SNAPSHOT (25/2/2025) MAJOR SHAREHOLDERS Shareholder Shares (m) % Shares on Issue ~2,049m Breathe International Ltd 576,268,527 28.12% Options & Performance Rights 42.9m Kirkman Tradin
Slide 23: Contact
Contact: Samuel Watson – Managing Director info@bioxyne.com James Emonson – Corporate Advisor, Alpine Capital jemonson@alpinecapital.au Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 23